The Filing Desk

Ocular Therapeutix

OCUL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OCUL · Last close · November 13, 2026
$6.21
Value Ocular Therapeutix yourself

Ocular Therapeutix's revenue fell 18.5% to $52 million in fiscal 2025. Its operating margin was −519.8%, down from −269.6% a year earlier. Free cash flow was −$217 million. The diluted share count rose 18.3%.

OCULAR THERAPEUTIX, INC Latest fiscal year ended December 31, 2025 10-K filed February 5, 2026 · 0001104659-26-010664 Updated
Revenue
$52M
18.5%
Operating margin
−519.8%
250.2 pts
Net income
−$266M
 
Free cash flow
−$217M
 
Return on equity
−54.9%
40.4 pts
Market cap
$1.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ocular Therapeutix does

Ocular Therapeutix is a drug company focused on eye disease. It sells one approved product, DEXTENZA, a small insert placed in the tear duct that releases a corticosteroid. It is approved for eye inflammation and pain after eye surgery and for itching from allergic conjunctivitis.

Its main development program is AXPAXLI, an implant of the drug axitinib in a hydrogel that dissolves slowly in the eye. It is in Phase 3 trials for wet age-related macular degeneration, an eye disease of older adults, and for diabetic retinal disease. A second candidate, OTX-TIC, a travoprost implant for glaucoma, finished a Phase 2 trial, and Ocular says it is evaluating next steps. All of its products use its own hydrogel technology, called ELUTYX, to release a known drug over time.

Ocular earns revenue from DEXTENZA sales and has a history of losses. It has debt that it says may limit its cash flow.

Its biggest risks, as it describes them

  • It has a history of losses and may never be profitable.
  • It may need more funding, which could dilute shareholders or limit its operations.
  • Its significant debt could limit cash it can invest in the business.
  • Clinical trials of AXPAXLI could be delayed by slow enrollment or other unexpected events.
  • Side effects found in trials could force it to limit or drop a program.
From Ocular Therapeutix's annual report on Form 10-K, filed February 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ocular Therapeutix lost money in fiscal 2025: a net loss of $266 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments164102196392737
Debt incl. finance leases—25666871
Net debt (negative means net cash)—−77−130−324−666
Net debt to EBITDA—————
Debt to equity—0.7x0.7x0.2x0.1x
Interest coverage−11.7x−11.2x−7.3x−12.7x−22.8x
Current ratio7.3x4.1x6.7x10.7x15.4x
Quick ratio7.2x4.1x6.6x10.6x15.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ocular Therapeutix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $461,354 of Ocular Therapeutix shares on the open market, and 6 insiders sold $2.8 million, $2.6 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 31, 2026Donald NotmanChief Operating OfficerSold1,099$10.24$11,254Form 4
Aug 24, 2026Pravin DugelSee Remarks, DirectorSold plan21,649$10.77$233,160Form 4
Aug 24, 2026Jeffrey S. HeierChief Scientific OfficerSold plan3,296$10.78$35,531Form 4
Aug 24, 2026Peter KaiserChief Development OfficerSold plan3,035$10.77$32,687Form 4
Aug 24, 2026Sanjay NayakChief Strategy OfficerSold plan1,897$10.78$20,450Form 4
Jun 3, 2026Nadia WaheedChief Medical OfficerSold plan14,828$8.27$122,628Form 4
May 26, 2026Pravin DugelSee Remarks, DirectorSold plan21,156$8.20$173,479Form 4
May 26, 2026Jeffrey S. HeierChief Scientific OfficerSold plan3,018$8.20$24,748Form 4
May 26, 2026Peter KaiserChief Development OfficerSold plan2,967$8.20$24,329Form 4
May 26, 2026Sanjay NayakChief Strategy OfficerSold plan1,858$8.20$15,236Form 4
Feb 23, 2026Pravin DugelSee Remarks, DirectorSold plan20,056$8.28$166,064Form 4
Feb 23, 2026Jeffrey S. HeierChief Scientific OfficerSold plan3,057$8.28$25,312Form 4
The latest 12 of 26 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 94 of 94 of 9
Rule of 40−117.1%−204.3%−436.0%
Altman Z''−5.49−0.823.49
Accruals ratio−5.2%−16.6%−9.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassFailFail
F-score3 of 94 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Ocular Therapeutix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ocular TherapeutixFY25−18.5%−519.8%−417.5%——4
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
Nektar TherapeuticsFY25−43.9%−253.7%−377.8%——2Compare
Aquestive TherapeuticsFY25−22.6%−159.5%−119.0%——2Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2224174452586452
Revenue growth7.8%1.9%3.5%112.4%311.7%150.1%18.3%13.5%9.0%−18.5%
Gross profit1222153947535845
Research and development2731374129505461128197
Operating income−43−62−59−86−63−78−79−82−172−270
Net income−45−63−60−86−156−7−71−81−194−266
Diluted EPS (US$)−1.80−2.20−1.57−1.91−2.56−0.98−0.97−1.02−1.22−1.42
Diluted shares (millions)2529384561828386158187
Cash flow
Cash from operations−34−50−49−78−54−66−60−70−135−205
Capital expenditure28221146112
Free cash flow−36−59−51−80−54−67−63−76−136−217
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation678981517183343
Balance sheet at fiscal year end
Cash and short-term investments68—5454228164102196392737
Debt incl. finance leases1618—2525—25666871
Total assets75557379262205149252458808
Total liabilities23293782186117114161143154
Shareholders' equity522636−476883591315654
Margins and ratios
Gross margin76.5%76.2%76.6%45.0%88.0%89.9%91.2%91.0%91.2%87.3%
Operating margin−2,296.0%−3,220.1%−2,970.8%−2,029.9%−361.1%−179.3%−152.7%−141.0%−269.6%−519.8%
Net margin−2,369.0%−3,296.2%−3,014.0%−2,043.3%−894.3%−15.1%−137.9%−138.1%−303.7%−511.9%
Free cash flow margin−1,903.5%−3,053.8%−2,568.6%−1,888.2%−312.6%−153.4%−123.0%−130.6%−213.4%−417.5%
Rule of 40 (growth + FCF margin)−1,895.7%−3,051.9%−2,565.2%−1,775.8%−0.8%−3.3%−104.6%−117.1%−204.3%−436.0%
Return on capital——————————
Return on equity−63.1%−162.2%−193.4%−535.7%−429.6%−8.0%−115.2%−127.6%−95.2%−54.9%
Return on assets−48.3%−97.2%−93.4%−113.8%−91.4%−2.8%−40.1%−40.2%−54.5%−42.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ocular Therapeutix's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ocular Therapeutix.